




FIG. 1A




FIG. 1B

	All subjects	Cohort 1	Cohort 2
N	10	6	4
Age, median (range)	60 (21, 78)	50 (21, 67)	67 (48, 78)
Female, N (%)	4 (40)	3 (50)	1 (25)
Subtype of sHLH diagnosis, N (%)			
mHLH	6 (60)	5 (83)	1 (25)
Unknown driver at baseline	4 (40)	1 (17)	3 (75)
Relapsed/refractory sHLH, N (%)	6 (60)	3 (50)	3 (75)
Previous anti-cytokine or biologic therapy, N (%)	4 (67)	2 (67)	2 (67)
Previous chemotherapy, N (%)	5 (83)	3 (100)	2 (67)
Days from sHLH diagnosis to study Day 1, median (range)	33 (0, 157)	24 (0, 90)	33 (14, 157)
Cancer type (at baseline or diagnosed on study), N (%)			
T cell lymphoma	5 (50)	3	2
Other lymphoma	1 (10)	1	0
Non-lymphoma cancer	2 (20)	2	0
Diagnostic, prognostic indicators (baseline)			
H-score ¹ , median (range)	171 (126, 260)	171 (126, 225)	196 (131, 260)
Ferritin, ng/ml, median (range)	14245 (3999, 97000)	30583 (3999, 97000)	14245 (8005, 85321)
sCD25 ² , pg/ml, median (range)	54653 (1324, 114457)	59529 (1324, 114457)	49778 (6015, 74910)
OHI index (+/-) ^{2,3} , N (%)	5 of 8 (63)	3 of 5 (60)	2 of 3 (67)
sCD25/ferritin ratio ^{2,4} , median (range)	1.5 (0.1, 6.2)	1.8 (0.1, 2.3)	0.9 (0.9, 6.2)

FIG. 2

	Patient number TN vs. R/R sHLH, driver sHLH	Highest dose escalation level (last dose)	Added treatment		Week 12 assessment
			Anti-cancer	Anti-HLH	
Cohort 1 Intra-patient dose escalation	1 R/R, T-cell lymphoma	0.1 mg/kg (Day 6)	ICE	-	No
	2 TN, T-cell ALL	0.1 mg/kg (Day 18)	HyperCVAD	-	Yes
	3 TN, Hodgkin lymphoma	1.0 mg/kg (Day 40)	AAVD	-	Yes
	4 R/R, R/R AML	1.0 mg/kg (Day 18)	Azacitidine and venetoclax	Yes ^{1,5,6}	No
	5 TN, R/R PTCL	3.0 mg/kg (Day 57)	GemEtop	Yes ^{3,6}	Yes
	6 R/R, R/R PTCL	1.0 mg/kg (Day 16)	GemOx	Yes ¹	No
	Patient number TN vs. R/R sHLH, driver sHLH	Progressed to weekly dosing (last dose)	Added treatment		Week 12 assessment
			Anti-cancer	Anti-HLH	
Cohort 2 Fixed dose regimen	7 R/R, unknown driver	No (Day 1)	-	-	No
	8 R/R, R/R PTCL	Yes, up to 1 mg/kg (Day 56)	GemOx ⁵	Yes ⁵	No
	9 R/R, T-cell lymphoma	Yes, up to 0.5 mg/kg (Day 15)	CHOP	Yes ^{3,4}	No
	10 TN, unknown driver	No (Day 4)	-	Yes ²	No

TN = treatment naive.
R/R = relapsed or refractory

FIG. 3




FIG. 4

Patient	Tumor	Response by Week 4 (except Patient 13 at Day 40)
5	PTCL-NOS	CR, PET and marrow Day 28 (+GemOx C1 Day 6)
8	PTCL-NOS	PR (transient), PET Day 28, score 5 to 3 (+GemOx C1 Day 13)
11	AITL	CR, marrow Day 28 (+romidepsin, 3 rd dose Day 7)
13	NK/T cell leukemia	CR, PET Day 40 (+CHOEP C3 Day 16)
16	AITL	Nodal CR, PET Day 25 (+romidepsin, Day 7 and 17)

PTCL-NOS: peripheral T cell lymphoma, not otherwise specified; AITL: angioimmunoblastic T-cell lymphoma; NK: natural killer; CTCL: cutaneous T cell lymphoma; T-ALL: T cell acute lymphoblastic leukemia, CR: complete response, PR: partial response.

FIG. 5